A Phase 0/Ia Study of BI 907828 (Brigimadlin) Concentrations in Brain Tissue and a Non-randomized Open-label, Dose Escalation Study of BI 907828 in Combination With Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Brigimadlin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 18 Feb 2025 Planned End Date changed from 20 Dec 2026 to 29 Aug 2025.
- 18 Feb 2025 Planned primary completion date changed from 1 Nov 2026 to 29 Aug 2025.
- 09 Dec 2024 Status changed from recruiting to active, no longer recruiting.